Drug intelligence / Profile preview

neuropeptide Y (1-36)

Development stage
Phase 2
Modality
Peptides
Administration
Ophthalmic, Intravitreal
01

Overview

Neuropeptide Y (1-36) is a 36-amino acid endogenous peptide that serves as a potent neurotransmitter and hormone within the central and peripheral nervous systems. It belongs to the pancreatic polypeptide family and is known for its wide-ranging biological roles, including the regulation of energy balance, memory, and neuroprotection. In the context of retinal and ocular health, NPY (1-36) exhibits neuroprotective properties but is also characterized by its ability to induce transient vasoconstriction, primarily through the activation of the Neuropeptide Y receptor type 1 (Y1). It acts as a non-selective agonist for several NPY receptor subtypes, including Y1, Y2, Y4, and Y5. While its therapeutic potential for neurodegenerative diseases like glaucoma is recognized, its clinical application is often limited by its vascular side effects compared to truncated analogs like NPY (3-36).

Other names
Full-length neuropeptide YNeuropeptide YNPY1-36NPY-1-36NPY 1-36
02

Targets

NPY5R (Neuropeptide Y receptor type 5)NPY2R (Neuropeptide Y receptor subtype 2)NPY4R (Neuropeptide Y receptor Y4)NPY1R (Neuropeptide Y receptor Y1)

Beyond the preview

Go deeper on neuropeptide Y (1-36).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on neuropeptide Y (1-36).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call